Deltex Medical is a British designer, manufacturer and marketer of the TrueVue fluid management system. The device allows clinicians to optimise the delivery of fluids and drugs to patients during surgery and intensive care. From its base in Chichester the company exports its health monitoring technologies to Europe, the US and further distributors worldwide.
Deltex Medical has further developed its haemodynamic monitoring system to simultaneously provide information on aortic blood flow and blood pressure throughout every heartbeat. The technology results in improved patient safety and patient outcomes, delivers significant cost reduction (per patient) and shorter hospitalisation times.
At the start of the coaching with Oxford Innovation, Deltex Medical’s challenges were their limited R&D budget, lack of experience in obtaining funding for innovative developments; and funding for the important clinical studies required; and access to the EU wide partnership frameworks needed to find suppliers with innovative products.
Oxford Innovation adviser Jakub Rakoczy under the Innovate to Succeed programme provided coaching support to tackle these challenges. The result was access to funding through skilled guidance of the writing process. The support allowed Deltex to submit to two R&D grant competitions in the EU’s H2020 fund. The adviser introduced Deltex Medical to a successful partner medical device company for UK-UK collaboration. This was a great success and it allowed Deltex to fine tune their submittal with a previous H2020 grant-funding winner. As a result Deltex secured funding for a Phase 1 study. Further support came in the form of creating a cooperation profile for seeking European partners, and an expert search was conducted.
To date the coaching outcomes from Oxford Innovation have resulted in winning 2 grant bids from Innovate UK and EU H2020 totalling £500k. Looking ahead, Deltex Medical has also been chosen to receive support from Enterprise Europe Network’s scale-up programme.
“Our experience of the support of the I2S programme is that it is first class. We could not have succeeded in our bid for funding without the help we received from our EEN contact. The opportunity this support affords Deltex Medical is truly exciting and we believe the product we intend to develop will significantly advance haemodynamic care globally, improve patient outcomes in major surgery and critical care and increase jobs”.
Dr. Graham Lowe. Chief Scientific Officer, Deltex Medical Ltd
Client business: Deltex Medical
Coach: Jakub Rakoczy